INVESTIGATING TYPE VI SECRETION IN ACINETOBACTER BAUMANNII AND ITS INTERPLAY WITH ANTIBIOTIC RESISTA
INVESTIGATING TYPE VI SECRETION IN ACINETOBACTER BAUMANNII AND ITS INTERPLAY WITH ANTIBIOTIC RESISTA
批准号:
9156408
负责人:
Mario Feldman
金额:
$38.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-22 至 2021-05-31
关键词:
Acinetobacter InfectionsAcinetobacter baumanniiAffectAmino AcidsAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsBacteriaBiogenesisBiologicalBiological AssayCatabolismCell Differentiation processCellsChemotactic FactorsCommunicable DiseasesCoupledDataDevelopmentEukaryotaFrequenciesGenesGoalsGram-Negative BacteriaHealthHealthcare SystemsHumanImmunityInfectionInjection of therapeutic agentIntoxicationInvestigationKiller CellsKnowledgeLeadMediatingMetabolicMetabolic PathwayMissionModelingModificationMulti-Drug ResistanceMultidrug-resistant AcinetobacterMutagenesisNosocomial InfectionsOrganismOutcomePathway interactionsPeptidoglycanPhenotypePhysiologicalPhysiological AdaptationPilumPlantsPlasmidsPopulationProcessProductionProkaryotic CellsProteinsProteomicsRecruitment ActivityRegulationResearchResistanceRoleSignaling MoleculeSuperbugSystemTestingTimeUnited States National Institutes of HealthWorkabstractingantimicrobialbasecell motilityclinically relevantcombatcomparativecostdriving forcefitnessin vivoinsightkillingsnovelnovel strategiespathogenphenylacetic acidpreventresearch studyresistant straintranscriptome sequencingtranscriptomicsweapons
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Multidrug resistant (MDR) Acinetobacter baumannii has emerged as a frequent cause of
nosocomial infections with some isolates resistant to all clinically relevant antibiotics. We have
previously identified a type VI secretion system (T6SS) in this organism. The multi-component
T6SS apparatus facilitates a dynamic contact-dependent injection of toxic effector proteins into
competing bacteria. The T6SS is energetically costly, and therefore in most bacteria appears to
be exquisitely regulated. We recently showed that several MDR A. baumannii isolates harbor a
large, self-transmissible resistance plasmid that negatively regulates T6SS. We found that T6SS
is silenced in plasmid-containing, antibiotic-resistant cells, while part of the population
undergoes frequent plasmid loss and activation of the T6SS. This activation results in T6SS-
mediated killing of competing bacteria but renders A. baumannii susceptible to antibiotics. We
propose that differentiation of A. baumannii cells into bacterial killers involves multiple
phenotypic and metabolic changes and that the fitness costs associated with the MDR and
T6SS phenotypes are the driving forces for this differentiation. RNAseq and differential
quantitative proteomics experiments revealed that unexpected metabolic pathways related to
amino acid catabolism were plasmid-regulated. Most of these metabolic changes seem to be
consequence of energetic adaptations to T6SS activation and carriage of a MDR plasmid. By
mutagenesis and comparative fitness assays we will determine the importance of these
metabolic changes. Interfering with these pathways may result in novel strategies to combat A.
baumannii infections. We will investigate how T6SS is regulated in MDR strains that do not
carry plasmids to extend our conclusions to these strains. The mechanisms by which the T6SS
apparatus crosses the peptidoglycan layer of the killer cell has not been determined in any
bacteria. We will define the role of a putative peptidoglycanase in this process. We have also
discovered phenotypic adaptations related to plasmid loss, involving piliation and motility. The
biological significance of these changes will be assessed. RNAseq data led us to the hypothesis
that a metabolic intermediate, phenylacetic acid (PAA), is employed as chemoattractant to
recruit prey and increase the killing efficiency. Determining the role of PAA in T6SS mediated
killing may result in a new paradigm for T6SS-mediated killing with important ecological
implications. The outcome of this work will be a detailed understanding of the interplay between
the T6SS and the MDR phenotype and the physiological changes associated to this activation,
which may lead to the development of new strategies to treat Acinetobacter infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Type VIII Secretion System in Gram-negative Bacteria
-
批准号:10642097
-
项目类别:
-
资助金额:$23.4万
-
财政年份:2023
-
负责人:Mario Feldman
-
依托单位:
Biogenesis and functions of outer membrane vesicles in Bacteroidetes
-
批准号:10553698
-
项目类别:
-
资助金额:$19.56万
-
财政年份:2022
-
负责人:Mario Feldman
-
依托单位:
Identifying niche specific adaptations in Acinetobacter baumannii
-
批准号:10596620
-
项目类别:
-
资助金额:$19.53万
-
财政年份:2022
-
负责人:Mario Feldman
-
依托单位:
Identifying niche specific adaptations in Acinetobacter baumannii
-
批准号:10449699
-
项目类别:
-
资助金额:$25.03万
-
财政年份:2022
-
负责人:Mario Feldman
-
依托单位:
Phenylacetic acid catabolism, a novel stress-response pathway in Acinetobacter baumannii
-
批准号:10621274
-
项目类别:
-
资助金额:$67.11万
-
财政年份:2022
-
负责人:Mario Feldman
-
依托单位:
Biogenesis and functions of outer membrane vesicles in Bacteroidetes
-
批准号:10431386
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2022
-
负责人:Mario Feldman
-
依托单位:
Development of a bioconjugate vaccine against Group B Streptococcus
-
批准号:9890994
-
项目类别:
-
资助金额:$28.01万
-
财政年份:2019
-
负责人:Mario Feldman
-
依托单位:
Molecular Insights into the Uropathogenesis of MDR Acinetobacter baumannii
-
批准号:10328879
-
项目类别:
-
资助金额:$66.85万
-
财政年份:2019
-
负责人:Mario Feldman
-
依托单位:
Molecular Insights into the Uropathogenesis of MDR Acinetobacter baumannii
-
批准号:10549371
-
项目类别:
-
资助金额:$66.85万
-
财政年份:2019
-
负责人:Mario Feldman
-
依托单位:
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
-
批准号:9341709
-
项目类别:
-
资助金额:$21.01万
-
财政年份:2017
-
负责人:Mario Feldman
-
依托单位:
海外基金